Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Wild-type”

156 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 156 results

Testing effectiveness (Phase 2)Ended earlyNCT01060423
What this trial is testing

TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer
Hans-Joachim Schmoll, MD 8
Testing effectiveness (Phase 2)UnknownNCT05278351
What this trial is testing

Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC

Who this might be right for
Colorectal Neoplasms Malignant
Shanghai Zhongshan Hospital 87
Large-scale testing (Phase 3)Looking for participantsNCT07491445
What this trial is testing

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more
Revolution Medicines, Inc. 900
Testing effectiveness (Phase 2)Study completedNCT05278728
What this trial is testing

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Who this might be right for
Colorectal Cancer
Biotech Pharmaceutical Co., Ltd. 31
Large-scale testing (Phase 3)Study completedNCT02395016
What this trial is testing

Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Biotech Pharmaceutical Co., Ltd. 90
Testing effectiveness (Phase 2)WithdrawnNCT03688230
What this trial is testing

Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.

Who this might be right for
Metastatic Colorectal Cancer
SFJ Pharmaceuticals X, LTD.
Large-scale testing (Phase 3)Study completedNCT03231722
What this trial is testing

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 435
Early research (Phase 1)WithdrawnNCT02630420
What this trial is testing

Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer

Who this might be right for
Colorectal Cancer
Yale University
Testing effectiveness (Phase 2)Study completedNCT04425239
What this trial is testing

Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Stage IV
National Cancer Institute, Naples 151
Testing effectiveness (Phase 2)Study completedNCT03142516
What this trial is testing

FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status

Who this might be right for
Colorectal NeoplasmsColorectal CarcinomaColorectal Cancer Metastatic+1 more
Grupo Espanol Multidisciplinario del Cancer Digestivo 20
Not applicableStudy completedNCT01732783
What this trial is testing

Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

Who this might be right for
Wild-type RAS Metastatic Colorectal Cancer
Amgen 213
Large-scale testing (Phase 3)Looking for participantsNCT06226857
What this trial is testing

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Who this might be right for
Colorectal NeoplasmsChemotherapy EffectMolecular Sequence Variation
City Clinical Oncology Hospital No 1 355
Large-scale testing (Phase 3)UnknownNCT04525326
What this trial is testing

Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases

Who this might be right for
Colorectal CancerLiver Metastases
Fudan University 584
Testing effectiveness (Phase 2)Ended earlyNCT04515394
What this trial is testing

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Who this might be right for
Colorectal Neoplasms
EMD Serono Research & Development Institute, Inc. 3
Early research (Phase 1)Ended earlyNCT01126450
What this trial is testing

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

Who this might be right for
Colon CancerRectal Cancer
Case Comprehensive Cancer Center 3
Testing effectiveness (Phase 2)UnknownNCT05799443
What this trial is testing

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer
Fujian Cancer Hospital 23
Not applicableUnknownNCT06322147
What this trial is testing

Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer

Who this might be right for
Colon Cancer
Qilu Hospital of Shandong University 50
Early research (Phase 1)Study completedNCT03317119
What this trial is testing

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

Who this might be right for
Metastatic Colon CarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Carcinoma+22 more
City of Hope Medical Center 26
Testing effectiveness (Phase 2)UnknownNCT03405272
What this trial is testing

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

Who this might be right for
Metastatic Colorectal Cancer
Sinocelltech Ltd. 110
Testing effectiveness (Phase 2)Looking for participantsNCT06776757
What this trial is testing

Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center 30
Load More Results